CA2496888A1 - Epitope sequences - Google Patents

Epitope sequences Download PDF

Info

Publication number
CA2496888A1
CA2496888A1 CA002496888A CA2496888A CA2496888A1 CA 2496888 A1 CA2496888 A1 CA 2496888A1 CA 002496888 A CA002496888 A CA 002496888A CA 2496888 A CA2496888 A CA 2496888A CA 2496888 A1 CA2496888 A1 CA 2496888A1
Authority
CA
Canada
Prior art keywords
polypeptide
epitope
cell
composition
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002496888A
Other languages
English (en)
French (fr)
Inventor
John J. L. Simard
David C. Diamond
Liping Liu
Zheng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2496888A1 publication Critical patent/CA2496888A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002496888A 2002-09-06 2003-09-05 Epitope sequences Abandoned CA2496888A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40912302P 2002-09-06 2002-09-06
US60/409,123 2002-09-06
PCT/US2003/027706 WO2004022709A2 (en) 2002-09-06 2003-09-05 Epitope sequences

Publications (1)

Publication Number Publication Date
CA2496888A1 true CA2496888A1 (en) 2004-03-18

Family

ID=31978717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002496888A Abandoned CA2496888A1 (en) 2002-09-06 2003-09-05 Epitope sequences

Country Status (8)

Country Link
US (2) US20040180354A1 (enExample)
EP (1) EP1545610A4 (enExample)
JP (2) JP2005537800A (enExample)
CN (1) CN1691964A (enExample)
AU (1) AU2003270311A1 (enExample)
CA (1) CA2496888A1 (enExample)
MX (1) MXPA05002455A (enExample)
WO (1) WO2004022709A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9035024B2 (en) 2004-07-23 2015-05-19 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
MXPA04005382A (es) 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
JP5127224B2 (ja) * 2003-06-17 2013-01-23 マンカインド コーポレイション 予防又は治療目的のためのmhcクラスi拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
US20050118186A1 (en) * 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
KR20070056042A (ko) * 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
EP1838342A2 (en) 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
CA2592922A1 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006080142A1 (ja) * 2005-01-25 2006-08-03 Nec Corporation Hla結合性ペプチド、それをコードするdna断片および組み換えベクター
US7511118B2 (en) * 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
NZ587601A (en) 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
EP2385059A3 (en) * 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
CA2665816C (en) 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CN101657213B (zh) * 2007-02-15 2014-02-26 曼康公司 用于增强t细胞应答的方法
EP3533461A3 (en) 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
EP2152890A1 (en) * 2007-05-23 2010-02-17 MannKind Corporation Multicistronic vectors and methods for their design
AU2009232774B2 (en) * 2008-03-31 2014-05-29 Tella Inc. Partial peptide of Survivin presented on MHC class II molecule and use thereof
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
EP2490713A2 (en) 2009-10-23 2012-08-29 MannKind Corporation Cancer immunotherapy and method of treatment
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US9345748B2 (en) 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CA2833404A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
CN103254294B (zh) * 2013-04-24 2015-04-01 北京博奥森生物技术有限公司 一种cd34-sg17多肽片段及其制备方法和应用
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック, インコーポレイテッド 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック, インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
EP3215165B1 (en) * 2014-11-05 2020-12-23 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
RU2017132190A (ru) 2015-03-18 2019-04-18 Омнисайт Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
TW201702272A (zh) * 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Prame肽專一性類t細胞受體抗體
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック, インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック, インコーポレイテッド シルベストロール抗体-薬物コンジュゲート及び使用方法
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2018212584B2 (en) * 2017-01-27 2020-12-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
BR112019018307A2 (pt) 2017-03-03 2020-03-31 Treos Bio Zrt Plataforma para identificação de peptídeos imunogênicos baseada em população
CR20210160A (es) * 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
ES3075078T3 (es) 2017-09-20 2026-07-27 Ph Pharma Co Ltd Análogos de tailanstatina
JP7054418B2 (ja) 2017-11-08 2022-04-13 ビオンテック ユーエス インコーポレイテッド T細胞を製造する組成物及び方法
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
CN110950949B (zh) * 2018-09-26 2022-04-05 香雪生命科学技术(广东)有限公司 一种识别ssx2抗原的t细胞受体
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
TWI867324B (zh) 2019-05-08 2024-12-21 美商百歐恩泰美國公司 T細胞製備組合物及方法
CN110157682B (zh) * 2019-05-29 2021-11-12 深圳先进技术研究院 人工靶向修饰的car-t细胞及其制备方法与应用
US20230132241A1 (en) * 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114524870A (zh) * 2020-11-23 2022-05-24 香雪生命科学技术(广东)有限公司 源自于ssx2抗原的短肽
CN115677846A (zh) * 2021-07-27 2023-02-03 香雪生命科学技术(广东)有限公司 针对抗原ssx2的高亲和力t细胞受体
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN120417934A (zh) 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
KR20260012304A (ko) 2023-04-17 2026-01-26 피크 바이오, 인크. 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
CN117607460A (zh) * 2023-11-28 2024-02-27 珠海碳云诊断科技有限公司 用于检测pgi蛋白的多肽及其相关产品和应用
TW202617186A (zh) 2024-06-28 2026-05-01 美商飛爾富來生物公司 Bcl-xl降解劑抗體結合物及其用途
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1296622C (en) * 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
CA2072620C (en) * 1989-11-03 2007-06-12 Donald L. Morton Urinary tumor associated antigen, antigenic subunits uses and methods of detection
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
EP1757695A3 (en) * 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5747271A (en) * 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
SG49008A1 (en) * 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5830755A (en) * 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6025191A (en) * 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
JPH11507843A (ja) * 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US5856136A (en) * 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9035024B2 (en) 2004-07-23 2015-05-19 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins

Also Published As

Publication number Publication date
AU2003270311A8 (en) 2004-03-29
WO2004022709A3 (en) 2004-05-21
EP1545610A4 (en) 2006-11-08
US20040180354A1 (en) 2004-09-16
MXPA05002455A (es) 2005-06-03
CN1691964A (zh) 2005-11-02
US20090285843A1 (en) 2009-11-19
JP2005537800A (ja) 2005-12-15
AU2003270311A1 (en) 2004-03-29
WO2004022709A2 (en) 2004-03-18
JP2010104370A (ja) 2010-05-13
EP1545610A2 (en) 2005-06-29

Similar Documents

Publication Publication Date Title
JP4874508B2 (ja) エピトープ配列
US20040180354A1 (en) Epitope sequences
CA2733866C (en) Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same
CA2529056C (en) Combinations of tumor-associated antigens in compositions for various types of cancers
KR20010024585A (ko) 종양-특이적 항원, 이들의 제조방법, 및 이들의 면역화 및진단에서의 용도
RS61667B1 (sr) Novi peptidi i kombinacija peptida i njihovih skela za upotrebu u imunoterapiji protiv kolorektalnog karcinoma (crc) i drugih malignih tumora
HK1152076A (en) Epitope sequences
EP1444261B1 (en) Immunogenic alk (anaplastic lymphoma kinase) peptides
EP1752160A2 (en) Epitope sequences
HK1165190A (en) Epitope sequences
HK1103975A (en) Epitope sequences
CA2390882A1 (en) Cancer immunotherapy and diagnosis using cytochrome p450 1b1
BERG et al. Tumér immunology
WO2004043988A2 (en) Ptprk immunogenic peptide

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued